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Anthony	F.	Folck			A	Cell-Based	Model	to	Study	Factors	that	Drive	Diffuse	Astrocytoma	Development		Secondary	gliomas	are	an	incurable	form	of	brain	cancer	that	are	diagnosed	in	people	at	a	median	age	of	45	years.	Next-generation	sequencing	has	found	that	secondary	glioblastomas	have	a	distinct	genetic	profile	from	the	more	common	primary	glioblastomas,	which	are	diagnosed	in	people	typically	over	the	age	of	60.	Over	80%	of	secondary	gliomas	contain	an	IDH1R132H	mutation,	resulting	in	neomorphic	mutations,	which	catalyze	isocitrate	to	the	oncometabolite	D-2-hydroxyglutarate	(2-HG)	instead	of	alpha-ketoglutarate	(α-KG).	As	2-HG	accumulates,	it	induces	a	hypermethylator	phenotype	that	prevents	the	cells	from	differentiating.	Acquisition	of	additional	mutations	in	tumor	suppressors	such	as	p53	and/or	ATRX	likely	leads	to	tumor	initiation.	Work	in	the	Wells	Laboratory	has	found	that	loss	of	the	HIPPO	adaptor	protein	AmotL1	is	also	associated	with	increased	malignancy.	AmotL1	inhibits	the	transcriptional	co-activator	YAP	to	suppress	both	cell	growth	and	migration.	To	understand	the	molecular	events	leading	to	secondary	glioma	development,	this	thesis	developed	a	series	of	astrocyte	cell	lines	that	carry	IDH1	and/or	p53	mutations.	These	lines	were	then	studied	in	2D	and	3D	cell	culture	systems	to	identify	changes	that	are	associated	with	early	secondary	glial	tumors.	Work	was	also	carried	out	to	enable	screens	for	small	molecules	that	can	be	tested	on	these	cell	lines.		 	 Clark	Wells,	PhD,	Chair	 	
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INTRODUCTION		
	 Gliomas	are	a	broad	category	of	non-neuronal	brain	cancers	that	mainly	arise	from	astrocytes,	but	can	also	comprise	of	oligodendrogliomas,	ependymomas	and	mixed	lineages.	Gliomas	are	clinically	differentiated	by	histopathologic	features	into	4	grades	that	associate	with	clinical	outcomes.	Grade	I	is	a	noncancerous,	slow-growing	tumor	that	has	clear	margins	and	can	usually	be	cured	with	surgery.	Grade	II-IV	tumors	diffusely	invade	into	the	normal	brain,	contain	a	large	number	of	actively	dividing	tumor	cells	(hypercellular),	and	show	active	angiogenesis.	Grade	II	tumors	are	distinguished	from	Grade	III	tumors	by	their	lack	of	necrosis	(the	accumulation	of	dead	cells).	Grade	IV	gliomas,	which	are	often	referred	to	as	glioblastomas,	are	highly	invasive	and	lethal	(Aldape	et	al.).		It	is	now	appreciated	that	glioblastomas	can	arise	through	two	very	different	mechanisms.	Glioblastomas	that	arise	from	the	progression	of	stages	I-III	tumors	are	termed	secondary.	Conversely,	primary	glioblastomas	are	thought	to	initiate	de	
novo	as	grade	IV	tumors	from	neural	stem	cells	(Ohgaki	and	Kleihues,	Reifenberger,	2014	#8).	While	primary	and	secondary	glioblastomas	are	histologically	indistinguishable,	they	significantly	differ	in	their	age	of	onset,	initial	malignancy	and	genetic	and	epigenetic	profiles	(Table	1)	(Ohgaki	and	Kleihues).	Primary	glioblastomas	account	for	45-50%	of	all	primary	brain	tumors	with	an	annual	incidence	of	~3	per	100,000	people	(Aldape	et	al.,	Dolecek,	2012	#7).	Primary	glioblastomas	rapidly	develop	de	novo	in	elderly	patients	without	clinical	or	histological	evidence	of	a	less	malignant	precursor	lesion	(Ohgaki	and	Kleihues).	Despite	multimodal	therapy,	including	neurosurgical	resection	and	radiotherapy	
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with	concomitant	and	adjuvant	temozolomide	(TMZ)	(Stupp	et	al.),	the	overall	prognosis	of	primary	glioblastoma	patients	remains	poor	with	a	median	overall	survival	of	12.5	months	(Weller	et	al.).	Secondary	glioblastomas	typically	arise	within	the	frontal	lobe	in	adult	patients	(Ferris	et	al.)	as	low-grade	diffuse	astrocytomas	that	usually	take	several	years	to	progress	to	a	lethal	status	(Hegi	et	al.).	Secondary	glioblastomas	were	named	based	on	their	rise	from	the	progression	of	lower-grade	gliomas	(LGGs)	e.g.	either	grade	II	or	III	(Louis	et	al.).	Patients	are	usually	diagnosed	at	a	much	younger	age	with	a	diffuse	glioma	(median	age	of	39	years)	where	the	progression	to	a	secondary	glioblastoma	can	often	take	7-10	years.	These	tumors	characteristically	have	less	necrosis	than	primary	glioblastomas	(Ohgaki	and	Kleihues).		The	molecular	basis	for	the	different	natural	history	of	secondary	glioblastomas	was	not	understood	until	large	scale	sequencing	studies	in	2008	found	that	most	secondary	gliomas	contain	mutations	in	the	active	site	of	isocitrate	dehydrogenase	1	(IDH1)	and	less	frequently	IDH2	(Parsons	et	al.).	IDH1/2	mutations	are	thought	to	drive	tumor	initiation,	as	they	are	the	earliest	detectable	genetic	alteration	in	precursor	low-grade	diffuse	gliomas	(Ohgaki	and	Kleihues).	Further	large	scale	sequencing	projects	comprising	over	1,000	tumors	have	found	that	~80%	of	all	WHO	grade	II-III	diffuse	gliomas	and	secondary	glioblastomas	have	mutations	in	either	IDH1	or	IDH2.	Approximately	90%	of	IDH	mutations	result	in	an	arginine-to-histidine	substitution	at	codon	132	of	the	IDH1	gene	(IDH1R132H).	The	remaining	IDH	mutations	either	substitute	other	amino	acids	at	the	R132	position	of	IDH1	or	a	Histidine	at	the	R172	residue	of	the	homolog	IDH2	(Waitkus,	Diplas	and	
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Yan).	A	mutation	of	IDH1	or	2	is	now	agreed	to	be	a	definitive	diagnostic	molecular	marker	of	secondary	glioblastoma	that	is	more	reliable	and	objective	than	clinical	or	pathologic	criteria	(Ohgaki	and	Kleihues).	A	shared	consequence	of	the	IDH1	mutation	is	the	near-complete	elimination	of	the	normal	oxidation	and	decarboxylation	of	isocitrate	to	alpha-ketoglutarate	(α-KG)	(S.	Zhao	et	al.)	and	the	neomorphic	overproduction	of	D-2-hydroxyglutarate	(2-HG)	via	NADPH-mediated	reduction	of	α-KG	(Agnihotri,	Aldape	and	Zadeh,	Dang,	2009	#6)	(Figure	1).	The	by-product	oncometabolite	2-HG	is	otherwise	produced	at	only	modest	levels	in	hypoxic	states	(Wise	et	al.).	Several	studies	implicate	2-HG	in	pro-tumorigenic	effects	of	IDH1	mutants.	Metabolite	analysis	reveals	that	2-HG	levels	are	10-100	fold	higher	in	IDH1	mutated	gliomas.	Functional	studies	find	that	introduction	of	2-HG	induces	epigenomic	changes	via	a	CpG	island	methylator	phenotype	(CIMP),	characterized	by	increased	global	DNA	methylation.	This	results	in	an	inhibition	of	normal	differentiation	processes,	enhanced	cell	proliferation	(Lu	et	al.,	Ward,	2010	#35)	and	has	been	suggested	to	block	progenitor	cells	from	terminally	differentiating	(Turcan	et	al.).		Along	with	IDH1	mutations,	tumor	development	likely	requires	inactivation	of	multiple	tumor	suppressors	(Jiao	et	al.).	Around	65%	of	diffuse	astrocytomas	carry	a	mutant	form	of	p53	and/or	ATRX	(α-thalassemia/mental-retardation-syndrome-X-linked)	(Yan	et	al.).	Mutations	in	IDH1	likely	occur	before	p53,	as	low-grade	gliomas	carry	IDH1	mutations	without	p53	mutations	in	17%	of	cases,	whereas	p53	mutation	occurs	without	IDH	mutations	in	only	2%	of	cases.	Also,	analysis	of	cases	where	multiple	biopsies	were	taken	from	a	patient	revealed	that	
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IDH1	mutation	always	occurred	before	the	acquisition	of	a	p53	mutation	(Watanabe	et	al.)	(Figure	2).	These	types	of	analysis	strongly	implicate	IDH	mutations	and	loss	of	other	tumor	suppresses	are	involved	the	initiation	of	secondary	gliomas.	However,	very	little	is	known	regarding	their	proclivity	to	stay	indolent	for	several	years	or	the	changes	that	occur	that	drives	their	progression	to	a	highly	malignant	status.	To	understand	factors	that	may	be	involved	in	the	progression	of	secondary	gliomas,	we	analyzed	the	genes	whose	transcript	levels	in	The	Cancer	Genome	Atlas	(TCGA)	analysis	of	grade	II/III	gliomas	showed	a	significant	association	with	altered	patient	survival.	This	revealed	a	strong	positive	correlation	between	high	levels	of	mRNA	for	angiomotin	family	members	AmotL1	and	AmotL2	with	longer	patient	survival	(Figure	3).	Further	more,	patients	with	IDH1/2	mutations	that	also	had	relatively	high	levels	of	AmotL1	had	a	significantly	longer	survival	than	those	with	relatively	low	levels	of	AmotL1.	This	led	us	to	investigate	whether	AmotL1	may	protect	patients	with	IDH1/2	mutations	from	malignant	progression.	This	was	also	based	on	work	by	several	groups,	including	the	Wells’	laboratory,	that	found	AmotL1	and	AmotL2	bind	and	regulate	apical	polarity	proteins	(Wells	et	al.)	as	well	as	many	components	in	the	HIPPO	signaling	pathway	(Adler	et	al.)	to	promote	the	differentation	and	loss	of	growth	in	epithelial	cells.		While	the	HIPPO	signaling	pathway	was	initially	discovered	based	on	its	crucial	role	in	organ	size	control,	it	is	now	well	appreciated	to	relay	anti-growth	signals	from	a	variety	of	stimuli	including	intercellular	contacts	(B.	Zhao	et	al.).	Normal	cells	cease	proliferation	upon	reaching	confluence	due	to	contact	with	other	
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cells.	Classic	studies	have	found	that	the	loss	of	contact	inhibition	is	a	fundamental	property	of	cancer	cells	that	allows	them	to	form	tumors		(Hanahan	and	Weinberg).	The	HIPPO	pathway	activates	the	Large	Tumor	Suppressor	(Lats1/2)	kinases	in	response	to	metabolic	stresses	and	intercellular	contacts.	These	kinases	then	phosphorylate	and	inhbit	the	transcriptional	co-activator	Yes-Associated	Protein	(YAP)	(Hao	et	al.).	This	prevents	YAP	from	turning	on	multiple	trancription	factors	in	the	nucleus	that	induce	pro-growth,	survival	and	invasion	programs	(B.	Zhao	et	al.).	YAP	also	directly	binds	and	is	regulated	by	Amot	family	members	including	AmotL1	and	AmotL2.	Amots	inhibit	YAP	through	sequestration	in	the	cytosol	and	by	inducing	YAP	degredation.	This	process	depends	on	the	direct	phosporylation	of	the	Amot	family	members	by	Lats1/2	(Adler	et	al.)	(Figure	4).	Consistent	with	HIPPO	signaling	modulating	the	malignancy	of	LGGs,	our	analysis	of	the	TCGA	Reverse	Phase	Protein	Array	(RPPA)	data	found	an	association	between	increased	survival	of	patients	and	relatively	high	levels	of	phosphorylated-YAP/total	YAP.	Further,	preliminary	work	by	the	Wells’	Laboratory	has	shown	that	expression	of		IDH1R132H	in	the	glioblastoma	cell	line,	U373MG-(U)	results	in	increased	levels	of	YAP,		decreased	levels	in	phospho-YAP,	and	enhanced	YAP	dependent	transcription	of	CTGF.	These	effects	were	enhanced	by	AmotL1	silencing	and	antagonized	by	AmotL1	overexpression.	This	suggests	that	IDH	mutations	are	promoting	YAP	activity,	but	are	limited	by	the	presence	of	AmotL1.	Another	major	unresolved	question	is	the	cellular	context	in	which	IDH	mutations	enable	glioma	formation.	In	mammalian	organ	development	and	maintenance,	stem	and	progenitor	cells	give	rise	to	each	other	and	to	
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specialized/differentiated	cell	types.	The	equilibrium	that	governs	such	plasticity	is	dictated	and	sustained	by	the	activities	of	transcription	factors,	chromatin	regulators,	and	associated	cellular	networks	(Suva	et	al.).	Increasing	evidence	suggests	that	certain	tumors	depend	on	the	same	cellular	hierarchy,	where	sub-populations	of	cells	drive	tumor	propagation	and	growth.	Coincidentally,	transcription	factors	that	direct	developmental	decisions	in	the	cells	can	also	function	as	oncogenes	by	promoting	the	re-acquisition	of	developmental	programs	required	for	tumorigenesis	(Suva,	Riggi	and	Bernstein).		It	is	believed	that	human	astrocytes	exist	in	two	defined	functional	states:	a	fetal,	highly	proliferative	astrocyte	precursor	cell	(APC)	state	and	a	postnatal,	non-proliferative,	mature	state	(Zhang	et	al.).	After	proceeding	through	a	maturation	process,	astrocytes	lose	their	abilities	to	divide	and	instead	sheath	synapses	and	surround	blood	vessels	to	form	the	blood-brain	barrier.	Understanding	how	molecular	profiles	of	human	astrocytes	mature	is	critical	for	mapping	brain	development	and	pathologies	where	astrocytes	acquire	fetal	phenotypes	(Zhang	et	al.).	To	date,	it	is	poorly	understood	how	deregulation	of	this	process	may	underlie	LGG	development.	There	is	strong	evidence	that	stem-like	cells	drive	primary	glioblastoma	development	and	growth	as	well	as	therapeutic	resistance	(Bao	et	al.,	Chen,	2012	#5).	However,	it	is	unclear	whether	secondary	astrocytomas	arise	from	progenitor	or	adult	astrocytes.	That	study	revealed	that	TPX2	and	TNC	were	only	expressed	at	high	levels	in	APC	cells	whereas	mature	astrocytes	only	expressed	high	levels	of	HSD17B6	and	TLR4	(Zhang	et	al.)	(Table	2).	
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This	current	study	has	developed	a	series	of	astrocyte	cell	lines	to	study	the	early	events	in	astrocytoma	development.	This	involved	making	hTERT	immortalized	primary	progenitor	astrocytes	that	expressed	either	IDH1R132H	alone	or	in	combination	with	p53R273H.	Studies	were	then	carried	out	to	define	whether	these	cells	lost	progenitor	status	and/or	gained	features	of	differentiated	adult	astrocytes	when	they	were	cultured	in	3D	Matrigel©	system.	This	information	will	form	the	basis	for	future	studies	to	examine	how	deregulation	of	HIPPO	signaling	may	then	further	advance	tumorigenic	properties	that	may	promote	the	initiation	and/or	progression	of	tumors	from	such	cells.		 	
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	Table	1.	Primary	and	Secondary	Glioblastomas:	Comparison	of	Clinical	Versus	
Genetic	Diagnosis.	Primary	Glioblastoma	affects	a	much	older	population	than	Secondary	Glioblastoma.	The	presence	of	the	IDH1	mutation	is	a	defined	molecular	marker	in	segregating	Primary	from	Secondary	(0%	vs	100%),	followed	by	mutations	in	p53	and	ATRX.	(Table	was	adapted	from	Ohgaki,	2013)	
aTumors	were	considered	to	be	primary	if	the	diagnosis	of	glioblastoma	was	made	at	the	first	biopsy,	without	clinical	or	histological	evidence	of	a	pre-existing,	less	malignant	precursor	lesion,	where	as	the	diagnosis	of	secondary	glioblastomas	required	histological	and/or	clinical	(neuroimaging)	evidence	of	a	preceding	low-grade	or	anaplastic	astrocytoma.		
		 	
	 Primary	
Glioblastoma	
Secondary	
Glioblastoma	
Clinical	
Criteriaa	
Genetic	
Criteria	
(IDH1wt)	
Clinical	
Criteriaa	
Genetic	
Criteria	
(IDH1mut)	
Fraction	in	a	population	 94.7%	 91.2%	 5.3%	 8.8%	
Mean	age	(y)	 59-62	 56-61	 33-45	 32-48	
Mean	clinical	history	(m)	 6.3	 3.9	 16.8	 15.2	
	
Median	overall	survival	(m)	 	
Surgery	+	radiotherapy	 4.7	 9.9	 7.8	 24	
Surgery	+	
radio/chemotherapy	 	 15	 	 31	
	
Histologic	features	 	
Oligodendroglial	comp.	 18%	 20%	 42%	 54%	
Necrosis	 89%	 90%	 63%	 50%	
	
Genetic	Alterations	 	
IDH1	mutations	 4-7%	 0%	 73-88%	 100%	
p53	mutations	 17-
35%	 19-27%	 60-88%	 76-81%	
ATRX	mutations	 4-7%	 	 57-80%	 	
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	Figure	1.	A	Conceptual	Model	for	the	Functions	of	IDH1	Mutations.	IDH1	is	a	critical	member	in	the	Citric	Acid	Cycle	by	converting	isocitrate	to	α-KG,	which	generates	ATP	for	cellular	energy.	IDH1	mutants	are	heterozygous	and	reduce	the	activity	of	the	wild-type	IDH1,	resulting	in	a	gain-of-function	mutation	that	produces	the	oncometabolite	2-HG	from	α-KG.	Overabundant	levels	of	2-HG	result	in	inhibition	of	PHD	enzymes,	TET	enzymes,	and	Histone	Demethylases,	which	leads	to	a	series	of	detrimental	downstream	consequences.	(Figure	was	adapted	from	Agnihotri,	2014)		 	
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	Figure	2.	A	Conceptual	Model	for	the	Progression	of	Secondary	Glioblastoma.	A	series	of	events	must	occur	for	a	tumor	to	progress	into	malignancy.	Secondary	Glioblastoma	must	develop	mutations	early	as	a	progenitor	“precursor”	cell,	where	over	time,	more	mutations	will	compound.	Key	mutations	include	IDH1/2	and	p53/ATRX,	followed	by	the	gradual	loss	of	AmotL1	and	19q/10q.	(Figure	was	adapted	from	C.	Wells)		 	
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		 	Figure	3.	AmotL1	Expression	Correlates	With	Low	Malignancy	in	
IDHmut	Gliomas.	A)	IDH1/2Mut	LGGs	in	the	TCGA	were	stratified	by	grade	and	AmotL1	levels.	B)	The	survival	of	patients	with	LGGs	in	TCGA	with	IDH1/2Mut	were	stratified	by	high	or	low	AmotL1.	HR=Hazard	Ratio	which	was	computed	by	Cox	proportional	Ratio.	(Figure	was	adapted	from	unpublished	data	from	C.	Wells) 
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Figure	4.	Overview	of	the	HIPPO	Signaling	Pathway	in	the	Human	Astrocyte.	The	transcriptional	coactivator	YAP	is	highly	regulated	by	the	HIPPO	pathway	in	human	astrocytes.	Lats1/2	inhibit	YAP	dependent	growth	in	response	to	cell-cell	contact,	by	phosphorylating	and	inactivating	YAP,	ultimately	leading	to	proteasome	degradation	via	phosphorylation.	Alternatively,	AmotL1	can	inhibit	YAP	through	sequestration	techniques	and	induce	proteasome	degradation	or	couple	with	Lats1/2.	If	the	HIPPO	pathway	is	inactive,	YAP	is	able	to	localize	in	the	nucleus	and	interact	with	TEAD4	to	activate	transcription	factors,	ultimately	leading	to	proliferation,	survival,	and	stem	cell	self	renewal.			 	
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Table	2.	Top	Gene	Expression	Differences	Between	APC	and	Mature	Astrocytes	Genes	are	ranked	by	fold	change	in	expression	between	APC	and	mature	stages.	Top	genes	are	listed.	All	genes	have	>2-fold	enrichment	in	astrocytes	over	other	cell	types.	(Table	was	adapted	from	Barres,	2016)		 Gene	 Expression	in	Fetal	Astrocytes	 Expression	in	Mature	Astrocytes	 Fold	Change	
Top	Mature	Astrocyte	Genes	AGXT2L1	 0.1	 238.6	 1,988.6	S100A1	 0.1	 84.9	 849.4	SLC14A1	 0.1	 29.3	 334.6	*TLR4	 0.1	 18.7	 212.9	*HSD17B6	 0.1	 20.5	 204.6	
Top	APC	Genes	HIST1H2AI	 57.9	 0.1	 578.9	HIST1H3E	 51.0	 0.1	 509.6	*TPX2	 22.0	 0.2	 93.9	*TNC	 26.6	 0.6	 45.5	E2F5	 10.1	 1.4	 7.0	*Genes	used	in	qRT-PCR	for	expression	change	experimentation	 	
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MATERIALS	AND	METHODS	
	
IDH1	R132H	Mutant	Cloning	Human	IDH1	R132H	was	purchased	as	a	gBlock®	Gene	Fragment	(#132285073)	from	Integrated	DNA	Technologies	(IDT).	Preparation	of	mCherry	tagged	(V3610)	and	3X	Flag	(V3409)	lentiviral	vector:	1	μg	of	vector	was	linearized	by	restriction	digest	in	20	ul	with	the	restriction	endonucleases	Asc1	and	Pac1.	The	5’	phosphates	were	removed	from	the	vector	with	1	μl	of	alkaline	phosphatase	and	digested	for	15	minutes	at	37°C.	The	samples	were	then	isolated	via	gel	electrophoresis	and	purified	using	Qiagen®	Qiaex®	II	Gel	Extraction	Kit	(#20051).	The	gBlock®	DNA	gene	fragments	were	suspended	in	20	μl	TE	(10	mM	Tris,	0.1	mM	EDTA,	pH	7.5).	10	μl	of	the	suspension	was	used	in	a	20	ul	digestion	with	the	Asc1	and	Pac1	restriction	endonucleases.	The	gBlock®	digestion	was	heated	at	37°C	for	150	minutes,	then	heat	inactivated	at	70°C.	A	ligation	using	50	ng	vector	and	20	ng	digested	gBlock®	gene	fragment	was	carried	out	with	T4	DNA	ligase	buffer	(diluted	to	1X)	and	400	U	T4	DNA	ligase,	for	a	total	volume	of	20	μl	for	2	hours	at	16°C.	One	tenth	(2	μl)	of	the	ligation	reaction	was	then	transformed	into	chemically	competent	DH5	alpha	cells.	The	transformed	bacteria	were	grown	on	an	ampicillin	resistant	agar	plate	overnight,	developing	individual	colonies.	These	colonies	were	picked	and	grown	in	1x	LB	and	1X	Ampicillin	(100	ug/ml)	for	16	hours	at	37°C.	They	were	then	miniprepped	and	test	digested	for	validation.		IDH1	R132H	gBlock®	Sequence	(R132H	mutation	is	bold	and	underlined):	5’	-CCAGGGTTTCTTTGGAATTATTCATACTTATCCTGTCCCTTTTTTTTCCCCAGGGGCGCG
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CCTCCAAAAAAATCAGTGGCGGTTCTGTGGTAGAGATGCAAGGAGATGAAATGACACGAATCATTTGGGAATTGATTAAAGAGAAACTCATTTTTCCCTACGTGGAATTGGATCTACATAGCTATGATTTAGGCATAGAGAATCGTGATGCCACCAACGACCAAGTCACCAAGGATGCTGCAGAAGCTATAAAGAAGCATAATGTTGGCGTCAAATGTGCCACTATCACTCCTGATGAGAAGAGGGTTGAGGAGTTCAAGTTGAAACAAATGTGGAAATCACCAAATGGCACCATACGAAATATTCTGGGTGGCACGGTCTTCAGAGAAGCCATTATCTGCAAAAATATCCCCCGGCTTGTGAGTGGATGGGTAAAACCTATCATCATAGGTCACCATGCTTATGGGGATCAATCAGAGCAACTGATTTTGTTGTTCCTGGGCCTGGAAAAGTAGAGATAACCTACACACCAAGTGACGGAACCCAAAAGGTGACATACCTGGTACATAACTTTGAAGAAGGTGGTGGTGTTGCCATGGGGATGTATAATCAAGATAAGTCAATTGAAGATTTTGCACACAGTTCCTTCCAAATGGCTCTGTCTAAGGGTTGGCCTTTGTATCTGAGCACCAAAAACACTATTCTGAAGAAATATGATGGGCGTTTTAAAGACATCTTTCAGGAGATATATGACAAGCAGTACAAGTCCCAGTTTGAAGCTCAAAAGATCTGGTATGAGCATAGGCTCATCGACGACATGGTGGCCCAAGCTATGAAATCAGAGGGAGGCTTCATCTGGGCCTGTAAAAACTATGATGGTGACGTGCAGTCGGACTCTGTGGCCCAAGGGTATGGCTCTCTCGGCATGATGACCAGCGTGCTGGTTTGTCCAGATGGCAAGACAGTAGAAGCAGAGGCTGCCCACGGGACTGTAACCCGTCACTACCGCATGTAACCAGAAAGGACA	-	3’	
	
P53	R273H	Mutant	Cloning	A	complete	pLenti6/V5-p53_R273H	construct	was	order	and	received	from	Addgene	(Plasmid	#22934).	The	p53	R273H	gene	was	PCR	amplified	using	the	primers	O2609	(ACGTGGCGCGCCGAGGAGCCGCAGTCAGATCCTAGC)	and	O2610	(ACGTTTAATTAATCAGTCTGAGTCAGGCCCTTCTG).	The	PCR	product	was	gel	
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purified	and	then	digested	with	Asc1	and	Pac1.	This	was	then	gel	purified	again	and	ligated	into	the	mCherry	tagged	lentiviral	vector	(V3610)	with	restriction	enzymes	Asc1	and	Pac1.			
TEAD1	Cloning	A	full-length	version	of	TEAD1	(V3441)	was	cut	with	Asc1	and	Mfe1	restriction	enzymes	to	truncate	the	front	80	base	pairs	in	order	to	replace	it	with	a	synthesized	gBlock®	gene	fragment	from	Addgene	(O2594),	using	the	same	protocol	as	above.		
TEAD4	Cloning	A	smaller	manipulated	version	of	TEAD4	was	amplified	out	of	the	p-GEX-6p-1	construct	using	forward	primer	144932201	(TEAD	MG	Vector_F	--	ATATAGATCTATGCAGGACCCGGACACGTACAAC)	and	reverse	primer	144932202	(TEAD	MG	Vector_R	–	ATATAAGCTTTCATTCTTTCACCAGCCTGTAG)	with	the	phusion	enzyme.	It	was	then	loaded	in	a	0.8%	agarose	gel	and	run	out	for	45	minutes	at	100	volts.	The	band	was	extracted,	purified,	and	digested	with	HindIII	and	BglII	enzymes.	It	was	once	again	run	on	a	0.8%	agarose	gel	and	purified.	The	Pet28a	(+)	vector	was	received	from	the	Georgiadis	Laboratory	at	the	Indiana	University	School	of	Medicine	and	digested	with	HindIII	and	BamH1.	The	vector	was	then	gel	purified	and	ligated	using	T4	ligase	with	the	TEAD4	insert	overnight.	The	constructs	were	then	transformed	onto	a	kanamycin	resistant	plate	and	grown	at	37°C	overnight.	The	colonies	grew	and	were	inoculated	overnight	in	1x	LB	and	50	
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ug/ml	Kanamycin	at	37°C.	The	inoculations	were	miniprepped	and	validated	by	restriction	digest	and	gel	electrophoresis.	The	samples	were	finally	sent	for	sequencing	using	T7	and	T7-Term	primers.	Once	validated,	the	constructs	were	given	to	the	Georgiadis	Laboratory	for	further	experimentation.		
	
Cell	Line	and	Culturing		 Human	Embryonic	Astrocyte	TERT	Immortalized	(hEAT)	cells	were	purchased	from	Applied	Biological	Materials	Inc.	labeled	as	cell	line	T0281.	They	were	passaged	at	37°C	with	5%	CO2	on	10	cm2	dishes	in	Prigrow	IV	Medium	supplemented	with	10%	Fetal	Bovine	Serum	(FBS)	and	5	ml	of	Penicillin/Streptomycin.	Once	plates	were	confluent,	growth	media	was	aspirated	and	cells	were	washed	with	1x	PBS	and	then	detached	from	the	plate	by	adding	1	ml	of	trypsin	supplemented	with	5	mM	ethylenediaminetetraacetic	acid	(EDTA).	After	~10	minutes	of	incubation	at	37°C,	adding	3	ml	of	Dulbecco’s	Modified	Eagle	Medium	(DMEM)	supplemented	with	10%	FBS	and	5	ml	of	Penicillin/Streptomycin	quenched	the	reaction	and	the	combination	was	transferred	to	15	ml	conical	tubes.	These	tubes	were	centrifuged	at	1500	RPM	for	1.5	minutes,	and	the	media	was	aspirated.	The	pellet	of	cells	was	suspended	in	complete	Prigrow	IV	and	split	into	assays	after	being	counted	on	a	hematocytometer.	hEAT	cell	lines	were	created	in	four	separate	conditions:	RFP	Control,	IDH1R132H,	IDH1R132H	+	p53R273H,	and	p53R273H	alone.				
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Growth	Assays		 Growth	assays	were	completed	by	plating	150,000	cells	with	150	μl	of	a	reconstituted,	lamin-rich,	basement	membrane	(Matrigel©)	and	grown	for	24-96	hours	at	37°C.	Images	were	acquired	on	the	1500Z	Nikon	Stereoscope.		
	
Viral	Transfection	
	 In	1	ml	of	serum-free	media	the	following	transfection	mixture	was	prepared:	20	μg	of	target	cDNA,	10	μg	pRRE	and	pRSV-REV,	and	6	μg	VSVG.	25	μl	of	polyethylenimine	(PEI)	(2	μg/ml)	was	then	added	to	the	mixture	while	being	vortexed.	Mixtures	were	incubated	at	room	temperature	for	5	minutes	and	added	drop	wise	to	a	10	cm2	plate	that	was	seeded	with	4	million	293T	cells.	Finally,	viral	media	was	collected	every	24	hours,	spun	down,	and	transferred	to	a	new	15	ml	conical	tube.	Collection	was	completed	for	a	total	of	48	hours.	
	
Viral	Infection		 24	hours	prior	to	viral	infection,	hEAT	cells	were	approximately	90%	confluent	on	a	10	cm2	plate,	were	trypsinized,	spun	down	at	1500	RPM,	and	re-seeded	on	6	cm2	dishes	at	a	count	of	250,000	cells/dish.	After	24	hours,	growth	medium	was	aspirated	and	dishes	were	incubated	for	4-6	hours	with	viral	media	that	was	diluted	anywhere	from	1:2	–	1:12	in	complete	DMEM,	depending	on	the	virus.	Finally,	viral	media	was	aspirated	and	cells	were	again	cultured	in	complete	media	for	24	hours	at	37°C.			
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DNA/RNA/Protein	Extraction		 hEAT	cells	were	plated	in	10	cm2	at	500,000	cells	per	plate,	per	condition,	in	10	mL	of	complete	Prigrow	IV	media.	They	were	grown	to	~95%	confluence	in	biological	triplicate.	The	DNA,	RNA,	and	Protein	were	extracted	following	a	modified	version	of	the	Qiagen®	AllPrep®	protocol	and	kit.	Cells	were	harvested	from	plates	with	1	mL	of	1x	PBS	and	transferred	to	a	1.5	mL	microcentrifuge	tube.	The	cells	were	spun	at	7800	RPM	for	5	minutes	at	4°C.	The	PBS	was	aspirated	and	600	ul	of	RLTplus	with	1%	2-Mercaptoethanol,	99%,	extra	pure	(BME)	was	added.	The	RLTplus	was	only	added	to	one	of	the	three	tubes	per	condition,	where	it	was	suspended,	combined	with	the	next	tube,	suspended,	and	recombined	with	the	third	replicate	tube.	The	tubes	were	then	raked	across	a	rack	10	times,	twice	in	a	minute.	The	vortexed	solution	was	homogenized	with	a	23G	needle	and	syringe	by	pipetting	up	and	down	10	times.	After	homogenizing,	the	solution	was	spun	through	an	AP-DNA	column	at	9100	RPM	for	60	seconds	at	room	temperature.	The	DNA	is	bound	to	the	column	and	transferred	to	a	new	AP-DNA	column	while	the	flow-thru	was	combined	with	900	μl	of	100%	ethanol	(ETOH).	This	ETOH/RNA/Protein	solution	was	loaded	and	spun	through	an	RNeasy	column	at	10,000	RPM	for	30	seconds,	where	the	RNA	was	bound	to	the	column	and	the	protein	was	collected	and	stored	in	1.5	mL	microcentrifuge	tubes.	The	RNA	column	was	next	washed	with	700	μl	of	RWT	buffer	and	spun	at	10,000	RPM	for	30	seconds.	The	DNA	column	was	then	washed	with	500	μl	AW1,	while	the	RNA	column	was	washed	with	500	μl	RPE,	both	spun	at	10,000	RPM	for	30	seconds.	The	flow-throughs	were	discarded	and	the	DNA	and	RNA	columns	were	washed	again	with	500	μl	of	AW2	and	80%	ETOH,	
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respectively,	for	13,300	RPM	for	5	minutes.	Both	DNA	and	RNA	columns	were	placed	into	new	1.5	mL	microcentrifuge	tubes	and	spun	at	13,300	RPM	for	15	minutes	to	dry	and	eliminate	the	solvent	peak.	After	the	spin,	they	were	left	in	the	hood	for	5	minutes	to	air	dry.	The	RNA	column	was	eluted	with	100	μl	of	DI	water	and	spun	at	13,300	RPM	for	1	minute	and	the	DNA	column	was	eluted	with	100	μl	of	heated	elution	buffer	(after	1	minute	incubation).	The	DNA,	RNA,	and	protein	samples	were	stored	at	-80°C.		
	
Western	Blotting		 Protein	was	lysed	via	RIPA	lysis	buffer	(25ml	of	1M	Tris	pH	8.0,	2mL	of	0.5M	EDTA,	5ml	of	Triton	X-100	(1%	final),	5ml	10%	SDS	(0.1%	final),	15ml	5M	NaCl,	total	volume	was	brought	up	to	500mL	with	ddH2O)	supplemented	with	100x	ProteCEASE™	protease	inhibitor	(600	μl/6	cm	dish)	after	cells	were	washed	twice	with	1x	PBS.	After	protein	extraction,	samples	were	incubated	on	ice	for	10	minutes	and	spun	down	at	10,000	RPM	for	10	minutes	at	4°C,	where	the	supernatant	was	transferred	to	a	new	microcentrifuge	tube.	Next,	a	bicinchoninic	acid	(BCA)	assay	was	used	to	determine	protein	concentration	for	each	sample.	Normalization	for	equal	protein	loading	was	completed	by	dilution	each	sample	in	RIPA	and	6x	loading	dye.	Finally,	samples	were	denatured	for	5	minutes	at	95°C	and	30	μg	of	protein	was	loaded	into	each	well	of	a	10%	sodium	dodecyl	sulfate-polyacrylamide	gel	and	separated	by	electrophoresis	(SDS-PAGE)	for	60	minutes	at	160V.			 Next,	protein	was	transferred	to	a	nitrocellulose	membrane	for	1	hour	at	24V.	The	membrane	was	blocked	with	5%	milk,	washed	with	tris-buffered	saline	
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with	0.05%	Tween-20	(TBST),	and	incubated	in	the	following	antibodies	diluted	in	TBST:	mouse	anti-p53	(Santa	Cruz	Biotechnology)	1:1000,	mouse	anti-flag	M2	(Sigma)	1:1000,	mouse	anti-GAPDH	(Millipore)	1:10,000.	After	primary	incubation,	the	membrane	was	washed	three	times	in	TBST	and	incubated	with	a	secondary	antibody	(goat	anti-rabbit	or	goat	anti-mouse)	diluted	1:20,000	for	30	minutes.	Bands	were	visualized	on	a	LiCor©	Odyssey	machine.			
Quantitative	Real-Time	Polymerase	Chain	Reaction	(qRT-PCR)		 Cells	were	grown	to	80%	confluence	before	aspirating	the	media	and	washing	with	1x	PBS.	Cells	were	then	lysed	in	0.5	ml	of	Tri	Reagent	LS,	collected,	and	incubated	at	room	temperature	for	5	minutes.	100	μl	of	chloroform	was	added	to	the	samples	and	spun	down	at	14,000	RPM	for	10	min	at	4°C.	The	clear	aqueous	supernatant	was	transferred	to	new	1.7	ml	microcentrifuge	tubes	and	RNA	was	precipitated	with	a	1:1	dilution	of	isopropanol,	once	again	spun	at	14,000	RPM	for	10	min	at	4°C.	Supernatant	was	removed	and	the	RNA	was	washed	with	500	μl	of	70%	ethanol	at	4°C	for	5	minutes	at	14,000	RPM.	The	supernatant	was	removed	and	the	pellets	were	re-suspended	in	20	μl	of	H2O,	once	dried.			 5	μl	of	RNA	was	incubated	with	the	follow	mixture:	10	μl	H2O,	4	μl	dNTPs	(10mM),	and	2	μl	of	oligo	dT	(50	μM).	The	mixtures	were	incubated	at	65°C	for	5	minutes	and	the	complimentary	deoxyribonucleic	acid	(cDNA)	was	synthesized	by	incubating	the	above	mixture	with:	10	μl	of	H2O,	4	μl	RT	Buffer,	and	2	μl	of	SuperScript	reverse	transcriptase.	The	samples	were	incubated	for	45	minutes	at	
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50°C	and	standardized	to	400	ng/μl	after	concentrations	were	determined	using	the	NanoDrop©	spectrophotometer.			 Lastly,	5	μl	of	cDNA,	10	μl	of	H2O,	10	μl	of	Bioline©	SYBR	Green	PCR	mix,	and	1	μl	(10	μM)	of	both	forward	and	reverse	primers	was	added	to	each	well	of	a	96-well	ABI-FastOpti	plate	and	assayed	via	the	Eppendorf	RealPlex	ABI-FastOpti	Protocol.	Forward	and	reverse	primers	used	for	this	study	are	as	follows:	AL1	(TATTGATGCTGTTGGTCAGCCA/	TAAGGAAGAAAGGAGCAAGCGA),	18S	(CCGATAACGAACGAGACTCTGG/	TAGGGTAGGCACACGCTGAGCC),	TLR4	(GACCTGTCCCTGAACCCTAT/	CGATGGACTTCTAAACCAGCCA),	TPX2	(ACCTTGCCCTACTAAGATT/	ATGTGGCACAGGTTGAGC),	and	TNC	(GTGCAGAACTCTCCTGTCCAAAT/	ATCTTTGCTCCTTGCAGTCTTTG).		 	
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RESULTS		 	To	date,	there	are	no	cell-based	models	that	characterize	secondary	glioblastoma	initiation	or	progression.	To	create	a	model	to	study	the	expression	of	genes	that	are	associated	with	the	development	of	this	cancer,	human	embryonic	astrocyte	TERT	immortalized	(hEAT)	cells	were	purchased	from	ABM	Biosciences.		Telomerase	reverse	transcriptase	(TERT)	activation	lengthens	the	telomeres	in	DNA	strands,	allowing	cells	that	would	normally	undergo	apoptosis	(after	reaching	the	Hayflick	limit)	to	continue	dividing.	These	cells	were	either	cultured	in	Prigrow	or	in	a	modified	Astrocyte	media	described	below.	Cells	were	transduced	with	lentiviruses	that	allowed	the	stable	expression	of	IDH1R132H	alone	or	in	combination	with	p53R273H.	Because	these	cells	had	only	previously	been	altered	through	their	immortalization	with	hTERT,	the	effects	of	IDH1R132H	and/or	p53R273H	should	closely	reflect	those	changes	during	tumor	initiation.	Other	studies	which	examined	these	effects	in	glioblastomas,	used	cell	lines	that	had	already	accumulated	all	of	the	changes	necessary	for	highly	malignant	tumor	formation.			
Validation	of	hEAT	cells	as	a	pure	astrocyte	origin	line	To	validate	that	hEAT	cells	acquired	from	ABM	were	composed	purely	of	progenitor	astrocytes,	the	Hudmon	Laboratory	at	the	Indiana	University	School	of	Medicine	immunostained	these	cells	for	markers	of	different	populations	of	brain-derived	cells.	First,	they	determined	whether	these	cells	were	incompetent	for	glutamate	uptake,	which	would	be	consistent	with	being	of	progenitor	and	not	mature/differentiated	astrocytes.	To	also	determine	if	these	cells	could	acquire	
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glutamate	uptake,	they	were	transfected	with	the	either	Excitatory	Amino	Acid	Transporter	1	(EAAT-1)	or	Excitatory	Amino	Acid	Transporter	2	(EAAT-2)	(Figure	5).	Cells	were	then	challenged	with	[3H]	glutamate	in	the	presence	or	absence	of	the	glutamate	uptake	blocker	TBOA.	The	inability	of	these	cells	to	uptake	glutamate	unless	transfected	with	either	EAAT-1	or	EAAT-2	is	consistent	with	them	not	being	differentiated.	To	validate	that	these	cells	were	of	astrocytic	origin,	hEAT	cells	were	also	immunostained	with	GFAP,	Microtubule-associated	protein	2	(MAP-2),	CD11b	(OX-42)	and	Oligodendrocyte	transcription	factor	(Olig-2)	(Figure	6).	Cells	strongly	immunostained	for	GFAP,	an	intermediate	filament	expressed	in	astrocytes,	but	showed	no	immunostaining	for	MAP-2,	OX-42	or	Olig-2.	The	lack	of	MAP-2	staining	indicates	that	hEAT	cell	cultures	do	not	contain	any	neurons.	The	lack	of	staining	with	OX-42	indicates	that	they	do	not	contain	monocytes,	macrophages	or	granulocytes.	The	lack	of	Olig-2	staining	shows	that	there	is	an	absence	of	oligodendrocytes	and	motor	neurons.	These	results	strongly	indicate	that	the	hEAT	cells	purchased	from	Applied	Biological	Materials	Inc.	are	a	pure	population	of	fetal/progenitor	astrocytes.		
	
Testing	the	effects	of	different	media	conditions	on	the	growth	of	hEAT	cells			We	next	compared	the	growth	of	hEAT	cells	in	Prigrow	IV,	the	recommended	media	by	Applied	Biological	materials	(ABM).	This	was	shown	in	2012	to	foster	astrocyte	growth	(Prabhu	et	al.).	Prigrow	IV	media	was	purchased	from	ABM	and	supplemented	with	10%	FBS	and	Penicillin/Streptomycin.	This	media	allowed	robust	cell	growth	in	both	2D	and	3D	conditions.	However,	due	to	the	exorbitant	
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cost	of	this	media,	we	explored	alternative	media	formulations.	We	initially	tested	whether	hEAT	cells	would	grow	in	Dulbecco’s	Modified	Eagle	Medium	(DMEM)	High	Glucose	supplemented	with	10%	Fetal	Calf	Serum	(FBS)	and	Penicillin/Streptomycin.	hEAT	cells	were	not	found	to	proliferate	under	these	conditions.	We	therefore	examined	how	hEAT	cells	would	grow	in	a	formulation	that	has	been	shown	to	work	well	for	growing	adult	rat	astrocytes	and	referred	to	as	Cortical	Astrocyte	Media	(Astro	Media).	Through	consultation	with	the	Hudmon	Laboratory	at	the	Indiana	University	School	of	Medicine,	we	developed	the	Astro	media,	which	consisted	of	DMEM	High	Glucose/10%	Fetal	Calf	Serum	(not	heat	inactivated)	with	Penicillin/Streptomycin,	2mM	glutamine,	1mM	Sodium	Pyruvate,	5ug/ml	NAC,	5ug/ml	insulin,	and	10uM	hydrocortisone.	hEAT	cells	grew	in	Astro	media	similarly	in	both	2D	and	3D	conditions	as	was	observed	in	Prigrow	IV	media.	Given	the	dramatically	lower	costs	for	making	Astro	media,	hEAT	cells	were	transitioned	to	grow	in	Astro	media	from	the	Prigrow	IV	media.	This	required	that	the	cells	be	grown	for	several	passages	in	50%	Astro,	50%	Prigrow	IV	and	then	transitioned	to	100%	Astro	media.			
Comparison	of	growth	of	hEAT	cells	in	2D	and	3D	culture	systems		The	environment	of	a	cell	or	tissue	dramatically	impacts	cellular	fate.	Intrinsic	regulators	of	the	microenvironment	include	transcription	factors	and	cell	division	factors.	Extrinsic	factors	in	the	microenvironment	include	cell-cell	interactions,	soluble	factors,	and	extracellular	matrix	(ECM)	interactions.	The	correlation	between	extrinsic	microenvironmental	signals	and	corresponding	
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changes	in	gene	expression	are	directly	associated	with	either	long-term	maintenance	or	lineage	specific	differentiation	in	stem	cells	(Liu,	Lin	and	Roy).		The	ability	to	study	the	human	brain,	and	the	cells	that	compose	it,	is	a	complex	challenge.	To	mimick	the	physiological	cellular	conditions	(Preynat-Seauve	et	al.),	a	3-Dimensional	culturing	environment	composed	of	Corning®	Matrigel®	Matrix	was	used.	We	predicted	that	progenitor	or	stem	cells	might	transition	to	a	more	differentiated	form	when	switched	from	a	2-Dimensional	to	a	3-Dimensional	environment	containing	Matigel®	(Liu	and	Roy).	This	is	inpart	because	Matrigel®	is	a	solubilized	basement	membrane	preparation	extracted	from	the	Engelbreth-Holm-Swarm	(EHS)	mouse	sarcoma,	which	is	rich	in	ECM	proteins	like	laminin,	collagen	IV,	heparin	sulfate	proteoglycans,	entactin/nidogen,	and	various	growth	factors	(Liu,	Lin	and	Roy).		 hEAT	cells	were	grown	on	both	2D	plastic	and	3D	Matrigel®	cultures	for	comparison.	Genes	identified	by	Barres	et	al	are	signatures	of	progenitor	or	differentiated	astrocytes.	They	were	used	as	indicators	of	whether	hEAT	cells	grown	in	3D	showed	a	transition	from	a	progenitor	state	to	a	more	differentiated	state	(Table	2).	The	sequences	for	the	primers	to	measure	these	genes	were	identified	from	the	Barres	publication	or	in	other	published	articles.	The	relative	levels	of	APC	specific	mRNAs	and	differentiation	specific	mRNAs	were	notably	decreased	in	cells	grown	in	3D	(Figure	7).	Thus,	these	cells	likely	transition	away	from	a	progenitor	status,	but	do	not	seem	to	be	appreciably	differentiating.	There	are	a	number	of	reasons	for	the	transition	to	remain	incomplete,	likely	from	inadequate	media	
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conditions.	Further	experiments	need	to	be	conducted	with	various	astrocyte	medias	that	promote	differentiation.		
Stable	Heterologous	expression	of	IDH	and	p53	Mutants	in	hEAT	Cell	Lines	The	majority	of	lower	grade	astrocytomas	(~80%)	have	mutations	in	IDH1	and	~65%	of	these	cells	also	contain	a	mutation	in	p53.	We	determined	this	overwhelmingly	involved	an	R	to	H	change	at	residue	132	in	IDH	and	an	R	to	H	change	at	residue	273	in	p53	(Ohgaki	and	Kleihues).	Lentiviruses	expressing	either	IDH1	R132H	or	p53	R273H	were	therefore	constructed.	Heat	cells	were	transduced	with	these	lentiviruses	in	a	stepwise	fashion	and	cultured	individually	to	create	cells	expressing	either	a	control	flag,	IDH1R132H,	p53R273H	or	the	combined	expression	of	IDH1R132H/p53R273H	(Figure	8).	Expression	was	then	validated	by	immunoblot	analysis	(Figure	9).			
Characterization	of	hEAT	cells	expressing	IDH	or	p53	mutations	in	2D	and	3D	
cultures	The	transduced	hEAT	cell	lines	mentioned	above	were	grown	to	confluence	in	10	cm	culture	dishes,	counted	on	a	hemocytometer,	and	split	into	either	3.5	cm	culture	dishes	(150,000	cells)	with	Matrigel©	or	6	cm	plates	(250,000	cells)	as	a	monolayer.	They	were	grown	for	5	days	(120	Hours)	at	37°C.	Images	were	taken	every	24	hours	and	recorded.	After	5	days	there	were	no	noticeable	differences	in	2D	culturing	between	the	various	conditions.		
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However,	after	5	days	there	were	significant	changes	in	the	morphology	of	the	cells	between	the	different	conditions	in	3D	(Figure	10).	In	control	cells,	the	images	showed	a	gradual	growth	and	noticeable	interactions	between	cells.	In	the	IDH1R132H	cell	line,	cells	remained	small	and	isolated	over	the	five-day	period.	The	IDH1R132H	+	p53R273H	cell	line	created	a	similar	but	less	pronounced	lattice	structure	observed	in	the	control	group,	although	this	began	to	deteriorate	after	5	days.	In	the	p53R273H	mutant	cell	line,	the	cells	grew	as	large	clumps.			
Preliminary	Data	for	Next-Generation	Sequencing		In	order	to	conduct	the	next-generation	sequencing	analysis,	DNA	and	RNA	had	to	be	purified	from	the	hEAT	cell	lines.	This	was	possible	by	using	the	AllPrep®	DNA/RNA/Protein	kit	by	Qiagen®.	hEAT	cell	lines	had	to	be	scaled	up	in	order	to	produce	enough	cells	for	DNA,	RNA,	and	protein	purification.	When	cells	reached	approximately	90%	confluence	in	each	cell	line,	they	were	lysed	and	homogenized	in	a	buffer,	which	inactivated	DNases,	RNases	and	proteases	to	ensure	intact	DNA,	RNA,	and	protein	was	retrieved.	The	lysate	was	then	spun	through	a	column	with	a	high-salt	buffer	that	selectively	bound	genomic	DNA.	The	DNA	was	washed	and	eluted,	rendering	it	suitable	for	analysis.	The	flow-through	from	the	initial	DNA	column	spin	was	added	to	an	RNeasy	column,	where	total	RNA	would	bind	to	the	membrane	and	contaminants	were	washed	away.	The	RNA	was	then	washed	and	eluted,	making	it	ready	for	analysis.	Protein	was	subsequently	retrieved	from	the	RNA	flow-through	and	stored	at	-80°C.		
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The	methylome	and	the	transcriptome	of	three	hEAT	cell	lines;	Flag	Control,	IDH1R132H	and	the	IDH1R132H	+	p53R273H	was	determined	by	next-generation	sequencing	through	the	IU	Bloomington	genomics	core.	Initial	results	from	the	principal	component	analysis	of	transcriptome	data	showed	a	clustering	of	Flag	control	cells	drastically	separate	from	both	the	IDH1R132H	and	IDH1R132H	+	p53R273H	cell	lines,	indicating	at	a	genetic	level,	there	was	a	difference	between	control	and	mutant	cell	lines	(Figure	11).	The	flag	control	samples	and	the	IDH1R132H	+	p53R273H	both	clustered	tightly	to	their	replicates,	where	as	the	IDH1R132H	had	variability	on	the	Y-axis	clustering.	This	was	accounted	for	during	the	transcriptional	pathway	analysis.	The	transcripts	which	showed	significant	differences	between	the	different	cell	line	conditions	were	subjected	to	INGENUITY®	pathway	analysis.	This	revealed	that	IDH1R132H	and	IDH1R132H	+	p53R273H	induced	686	and	1830	differentially	expressed	genes	between	these	two	conditions	compared	to	the	flag	control,	respectively.	Interestingly,	most	genes	altered	by	IDH1R132H	were	similarly	impacted	in	IDH1R132H	+	p53R273H	cell	lines	(Figure	12).	Additionally,	diseases,	biological	functions,	and	associated	networks	were	identified	(Figure	13).	This	revealed	a	vast	array	of	results.	In	the	presence	of	solely	the	IDH1R132H	mutant,	astrocytes	are	associated	with	cellular	movement,	growth,	proliferation,	signaling,	and	post-translational	modifications.	They	are	also	engaged	in	networks	relating	to	cancer,	injury,	developmental	disorders	and	cell	death/survival.	They	positively	regulate	genes	directing	brain	development,	damage	response,	proliferation,	neuronal	survival	and	inflammatory	response,	while	negatively	regulating	genes	directing	differentiation,	amino	acid	and	sodium	transport,	neurogenesis,	CNS	development,	
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metabolism,	and	intermediate	filaments.	The	addition	of	the	p53R273H	mutation	shares	many	similar	consequences	as	the	IDH1R132H	mutation,	but	has	unique	characteristics.	The	double	mutant	has	similar	biological	functions	such	as	cellular	movement,	signaling,	growth	and	proliferation,	but	also	shows	an	association	with	cellular	assembly,	organization,	function,	and	maintenance.	It	also	shares	networks	such	as	inflammatory	disease,	cancer,	injury	and	cell	death/survival,	but	associates	with	networks	like	movement	and	immune	cell	trafficking.	Finally,	the	double	mutant	has	unique	upregulated	genes	involved	in	tumor	initiation	and	downregulated	genes	involved	in	cell	polarity.	Although	the	two	mutant	cell	lines	share	many	similarities,	there	is	a	clear	difference	in	their	genetic	makeup	and	associated	networks.		
	
The	YAP-TEAD	interaction	may	be	a	potential	target	for	molecular	inhibition	The	Hippo	signaling	pathway	is	identified	as	one	of	several	pathways	known	to	mediate	the	majority	of	cell	fate	decisions	in	metazoans	(Pan).	The	HIPPO	pathway	regulates	differential	signaling	between	the	inside	and	outside	cells,	and	when	HIPPO	is	inactivated,	hypo-phosphorylated	YAP	localizes	to	the	nuclei	and	interacts	with	transcription	factors,	including	transcriptional	enhancer	activation	domain	family	members	(TEADs)	(Zhou	et	al.).	Conversely	for	the	inner	cells,	HIPPO	is	activated	and	YAP	is	phosphorylated	by	Lats	and	sequestered	in	the	cytoplasm	(Nishioka	et	al.).	A	major	player	in	the	Hippo	pathway	is	TEAD4,	which	is	one	member	of	a	family	of	TEA	binding	domain	(TEAD)	transcription	factors.	TEAD	is	critical	for	YAP	functions	in	gene	expression,	cell	proliferation,	anchorage-
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independent	growth,	and	epithelial-mesenchymal	transition	(Zhou	et	al.).	TEAD4	contributes	to	the	fate	of	cell	lineage	specification	and	its	transcript	levels	have	been	found	to	be	amplified	in	a	variety	of	cancers,	including	testicular,	brain,	ovarian,	head	and	neck.	YAP	is	a	transcriptional	co-activator	and	a	potent	growth	promoter	with	a	TEAD	binding	domain.	YAP	overexpression	has	been	shown	to	increase	organ	size	in	Drosophila	and	saturation	cell	density	in	NIH3T3	cells	(B.	Zhao	et	al.).	YAP	overexpression	and	increased	nuclear	localization	in	multiple	types	of	human	tumors	is	associated	with	stem	cell	properties	and	cancer	metastasis.	YAP	also	cooperates	with	Myc	oncogenes	to	stimulate	tumor	growth	in	nude	mice	(Chen,	Loh	and	Song).		YAP	functions	as	a	transcriptional	co-activator	since	it	lacks	a	DNA	binding	domain.	TEAD	mediates	Hippo	signaling	in	organ	size	control	by	functioning	as	a	YAP	partner.	TEAD	transcriptional	factors	interact	with	the	N-terminal	of	YAP	via	their	C-terminals.	In	the	structure	of	the	mouse	TEAD-YAP	complex,	TEAD	adopts	an	immunoglobulin-like	beta-sandwich	fold	flanked	by	four	short	alpha	helices,	while	YAP	resembles	a	belt	wrapped	around	TEAD	via	folding	into	two	alpha	helices	linked	by	a	PXXϕP	motif-containing	loop	(Chen,	Loh	and	Song).	The	C-terminus	of	TEAD	presents	a	rigid	interface	for	specific	interaction	with	YAP,	while	nuclear	magnetic	resonance	(NMR)	studies	have	revealed	that	the	N-terminal	TEAD	binding	domain	of	YAP	exists	in	an	unfolded	conformation	in	its	native	state	and	that	TEAD	binding	causes	localized	conformational	changes	in	YAP	(Tian	et	al.).	Only	a	small	fragment	in	the	N-terminal	region	of	YAP	is	involved	with	the	interaction	of	TEAD.	In	this	fragment	are	three	important	binding	regions	identified	by	Chen	et	al	2010,	
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which	include	two	alpha	helices	and	the	PXXϕP	motif	containing	linker	region,	which	are	required	for	interaction	between	YAP	and	TEAD	and	are	crucial	specificity	determinants.  Multiple	TEAD	constructs	were	created	as	potential	screening	targets	for	inhibiting	the	YAP-TEAD	interaction.	One	construct	was	TEAD1	with	an	80	base	pair	manipulation.	The	original	full	length	TEAD1	construct	(Figure	14)	contained	a	common	ATG	start	site.	However,	this	was	an	incorrect	start	site	for	the	fragment,	which	required	an	ATT	sequence	at	the	start	site.	A	front-end	gBlock®	gene	fragment	was	synthesized,	ordered,	and	received	from	Addgene.	It	was	constructed	in	the	pUC57	vector	(Figure	15).	From	there,	it	was	digested	out	of	pUC57	with	restriction	enzymes	Asc1	and	Mfe1	and	ligated	into	the	p-GEX-6p-1	plasmid,	which	contained	a	truncated	version	of	TEAD1	also	cut	with	Asc1	and	Mfe1	to	remove	the	improper	front	end.	This	newly	synthesized	fragment	contains	the	proper	ATT	start	site	for	TEAD1	instead	of	the	more	common	ATG	start	site.	Another	construct	created	was	a	smaller,	manipulated	version	of	TEAD4	(Figure	16)	that	was	PCR	amplified	out	of	a	different	p-GEX-6p-1	plasmid.	It	was	cloned	into	the	His-tagged	Pet28a	(+)	vector	with	restriction	enzymes	HindIII	and	BamHI.	Both	completed	constructs	were	handed	to	the	Georgiadis	Laboratory	at	the	Indiana	University	School	of	Medicine	to	be	tested	for	expression	and	sent	off	to	screen	for	small	molecule	inhibitors	of	the	YAP-TEAD	interaction.	 	
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	Figure	5.	Glutamate	Uptake	in	Fetal	Astrocytes	After	Heterologous	Expression	
of	EAAT-1	and	EAAT-2.	Naïve	hEAT	cells	do	not	take	up	glutamate	but	are	capable	of	gaining	sensitivity	to	glutamate	uptake	following	heterologous	expression	of	either	EAAT-1	or	EAAT-2.	Cells	were	also	challenged	with	glutamate	uptake	in	the	presence	of	glutamate	uptake	inhibitors	TBOA	and	UCPH-101.	(Experiment	carried	out	by	the	laboratory	of	A.	Hudmon	at	IUSM)			
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	Figure	6.	Fetal	Astrocytes	are	GFAP	Positive,	but	Negative	for	MAP-2,	OX-42	and	
Olig-2.	hEAT	cells	were	cultured	on	glass	coverslips	before	being	fixed,	permeabilized,	and	immunostained	for	GFAP	(astrocyte	marker),	MAP-2	(neuron	marker),	OX-42	(macrophage	marker),	Olig-2	(oligodendrocyte	marker)	and	DAPI	(nuclear	and	chromosome	marker).	(Experiment	carried	out	by	the	laboratory	of	A.	Hudmon	at	IUSM)		
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	Figure	7.	Relative	Change	in	the	Levels	of	mRNA	Signatures	of	Progenitor	and	
Differentiated	Astrocytes	in	hEAT	Cells	Grown	in	2D	or	3D	Environments.	Cells	were	cultured	on	plastic	or	in	Matrigel©	for	4	days	before	being	recovered	and	lysed	in	TRIzol®	to	isolate	total	mRNA.	cDNA	was	then	produced	using	reverse	transcription.	The	relative	levels	of	the	indicated	genes	were	measured	by	qRT-PCR.	Measurements	were	conducted	in	biological	triplicate	and	technical	duplicate.	Overall,	both	adult	differentiation	markers	and	APC	markers	were	found	to	be	reduced	in	hEAT	cells	grown	in	3D	vs	2D	cultures.		 	
aAstrocyte	Precursor	Cell	
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	Figure	8.	The	Proposed	Model	for	the	Secondary	Glioma	Initiation	Series.	The	overall	workflow	whereby	hEAT	cells	were	transduced	with	a	lentivirus	expressing	IDH1mut	or	IDH1mut	+	p53mut.	Control	hEAT	cells	were	infected	with	a	control	mCherry	tag,	mCherry	tagged-IDH1R132H	or	with	both	IDH1R132H	+	p53R273H	viruses.	The	predicted	cellular	properties	from	the	expression	of	these	proteins	is	also	indicated	on	the	left.				 	
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Figure	9.	Western	Blot	Validating	Overexpression	of	IDH1R132H	and	p53R273H.	Cell	lines	transduced	at	the	indicated	dilutions	with	lentiviruses	expressing	the	indicated	proteins	were	grown	in	appropriate	media	until	approximately	80%	confluent.	Then	lysed	and	analyzed	by	western	blot.	The	viral	media	was	diluted	with	complete	DMEM,	as	indicated	in	(X:X)	to	help	with	toxicity.		
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	Figure	10.	Secondary	Glioma	Initiation	Series	Plated	in	3D	Matrigel.	When	cultured	on	a	3-Dimensional	environment	(Matrigel®),	hEAT	cell	lines	showed	specific	phenotypes	depending	on	the	expression	of	Control,	IDH1R132H,	p53R273H	or	IDH1R132H	+	p53R273H	over	a	5-day	period.	The	control	hEAT	cells	formed	large	cells	that	strongly	connected	to	neighboring	cells.	Expression	of	IDH1R132H	alone	resulted	in	cells	that	failed	to	increase	in	size	or	form	connections	with	neighboring	cells.	Expression	of	p53R273H	resulted	in	a	moderate	reduction	in	intercellular	connectivity	initially,	but	a	collapse	of	these	connections	by	Day	5.	Expression	of	both	IDH1	and	p53	mutations	resulted	in	cells	that	partially	rescued	the	control	phenotype,	where	cells	were	larger	and	more	interconnected	versus	cells	expressing	IDH1R132H	alone.		
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	Figure	11.	Next-Generation	Sequencing	Results	Reveal	Significant	Difference	
Between	Flag	Control	hEAT	Cells	Versus	Mutated	hEAT	Cell	Lines.	A	principal	component	analysis	from	the	next-generation	sequencing	transcriptome	analysis	showed	a	clustering	of	Flag	control	cells	drastically	separate	from	both	the	IDH1R132H	and	IDH1R132H	+	p53R273H	cell	lines.		
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Figure	12.	A	Venn	Diagram	Showing	Shared	and	Unique	Genes	in	the	IDH1	and	
IDH1+p53	Mutant	Cell	Lines.	The	use	of	next-generation	sequencing	and	transcriptome	analysis	revealed	unique	genetic	signatures	between	the	IDH1R132H	and	IDH1R132H	+	p53R273H	cell	lines.	The	majority	of	genes	were	similar	in	their	regulation;	however,	both	mutants	showed	a	unique	set	of	genes	being	up	and	downregulated.	In	total,	IDH1R132H	had	686	differentially	expressed	genes	and	IDH1R132H	+	p53R273H	had	1830	differentially	expressed	genes.		 	
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Figure	13.	The	Cellular	Consequences	of	Genetic	Mutations	in	Astrocytes.	Transcriptome	analysis	revealed	unique	functions	and	networks	associated	with	mutant	cells	lines	relative	to	the	control	astrocytes.	Both	mutants	had	similarities	and	differences	in	their	results.	Results	highlighted	in	red	are	unique	to	the	cell	lines	they	are	associated	with.				 	
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	Figure	14.	Restriction	Map	of	TEAD1	in	pGEX-6p-1.	The	TEAD1:pGEX-6p-1	plasmid	construct	contains	restriction	enzyme	cut	sites	at	base	pair	locations	38	and	6223.	These	sites	were	digested	to	truncate	the	front	end	of	TEAD1	to	allow	remodeling.		 	
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	Figure	15.	Restriction	Map	of	TEAD1	Front	End	Piece	in	pUC57	Vector.	The	TEAD1FrontEnd	piece	was	created	with	restriction	enzyme	locations	at	429	and	512.	These	sites	were	cleaved	with	MfeI	and	AscI	enzymes	to	remove	the	piece	from	the	pUC57	plasmid	in	order	to	complete	the	TEAD1	construct	in	the	pGEX-6p-1	vector.			 	
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	Figure	16.	Restriction	Map	of	TEAD4	Insert	in	pGEX-6p-1.	A	smaller,	manipulated	version	of	TEAD4	was	inserted	into	the	pGEX-6p-1	plasmid	via	restriction	enzymes	AscI	and	PacI	at	base	pair	locations	4975	and	5640,	respectively.				 	
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DISCUSSION	
	
Creating	and	Characterizing	Secondary	Glioblastoma	in	Cell	Lines	Our	current	model	of	secondary	glioblastomas	indicates	that	the	presence	of	IDH1R132H	blocks	differentiation	of	astrocytes	(Figure	17).	This	mutation	is	then	compounded	with	additional	mutations	in	p53	or	ATRX,	which	add	resistance	to	the	cellular	stress	being	induced	by	IDH1	mutations	and	thereby	confer	survival	advantages	to	these	cells.	It	is	proposed	that	over	time,	these	cells	transform	into	lower	grade	gliomas.	The	7-10	year	indolent	phase	we	propose	is	exited	as	cells	progressively	lose	AmotL1	and/or	AmotL2,	which	subsequently	contributes	to	invasiveness	and	high	malignancy.	To	model	how	IDH1R132H	and	p53R273H	impact	normal	progenitor	astrocytes,	we	developed	a	series	of	cell	lines	in	which	these	mutations	were	introduced.	We	further	tested	how	growing	these	cells	in	a	3D	culturing	environment	might	promote	a	loss	of	progenitor	status	and	a	proclivity	to	acquire	characteristics	of	differentiated	astrocytes	(Liu,	Lin	and	Roy).	This	seems	to	be	occurring	based	on	the	morphology	of	these	cells	after	several	days	of	culturing	in	3D	Matrigel®.	RFP	control	cells	formed	intercellular	contacts	that	likely	involve	communication	and	signaling,	which	is	known	to	occur	between	astrocytes	in	an	in	vivo	setting.	This	is	known	to	correlate	with	an	overall	increase	in	cell	survival,	communication,	and	growth.	However,	cells	expressing	only	IDH1R132H	looked	to	initially	make	connections,	but	this	rapidly	deteriorated	by	48	hours.	The	IDH1R132H	+	p53R273H	expressing	cells	were	seen	to	thrive	better	than	cells	expressing	IDH1R132H	alone,	although	not	to	the	same	extent	as	the	control	cells.	Further,	they	showed	some	
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capacity	to	connect	with	neighboring	cells.	It’s	suggested	that	the	addition	of	the	p53R273H	dominant-negative	mutation	is	reducing	the	apoptotic	response	in	the	cells.	Accordingly,	there	was	a	large	difference	in	growth	between	the	IDH1R132H	+	p53R273H	mutants	compared	to	the	IDH1R132H	mutant	alone.	These	results	support	the	theory	that	the	mutated	form	of	IDH1	blocks	differentiation	in	otherwise	normal	astrocytes	and	increases	cellular	stress.	Further,	the	addition	of	a	specific	mutation	in	p53	helps	allow	the	mutated	cells	to	survive	in	the	presence	of	mutant	IDH1	stress.	This	is	the	basis	of	secondary	glioblastoma,	and	future	experiments	will	be	conducted	adding	AmotL1	and/or	AmotL2	mutations	to	follow	progression.	We	also	characterized	the	molecular	changes	in	these	cell	lines	through	the	use	of	next-generation	sequencing	experiments	that	measured	transcriptome	and	methylome	data.	Cytosine	methylation	can	significantly	affect	both	gene	expression	and	chromatin	remodeling.	It	regulates	spatial	and	temporal	gene	expression	and	is	critical	for	embryonic	development	and	differentiation	processes.	Cytosine	methylation	in	promoter	regions	often	reduces	gene	expression;	where	as	heterochromatin	(inactive	chromatin)	formation	is	driven	by	hypermethylation.	Accordingly,	88%	of	active	promoters	are	unmethylated	in	mammals.	However,	if	abnormal	hypomethylation	in	heterochromatin	occurs,	there	is	an	increased	risk	of	chromosomal	instability	and	loss	of	genomic	imprinting	(Illumina).	Importantly,	methylation	can	help	drive	differentiation	in	cells,	where	they	typically	don’t	revert	back	to	stem	cells.	By	determining	which	genes	are	being	hyper-	or	hypo-methylated,	it’s	possible	to	identify	a	progression	of	mutations	in	secondary	glioblastomas.		
	 47	
Additionally,	transcriptome	analysis	can	characterize	all	coding	and	non-coding	transcriptional	activity.	This	can	focus	on	a	subset	of	relevant	target	genes	and	transcripts,	or	profile	thousands	of	genes	simultaneously	to	create	a	whole	picture	of	cellular	function	(Illumina).	This	provides	an	overview	of	actively	expressed	genes	and	transcripts	under	mutated	conditions.		Based	on	the	results	from	the	next-generation	transcriptome	analysis,	there	appears	to	be	a	transition	from	a	progenitor	cell	to	a	more	invasive,	stem-like	cell.	Transcriptome	analysis	revealed	a	significant	clustering	difference	between	the	control	hEAT	cell	line	and	the	mutant	hEAT	cell	lines.	This	indicates	there	are	clear	molecular	changes	occurring	between	the	cell	lines	in	the	series.	Although	not	definite,	there	are	indications	that	this	transition	is	taking	place	across	the	three	cell	lines	by	genetic	regulation.	Both	the	IDH1R132H	and	the	IDH1R132H	+	p53R273H	cell	lines	show	an	association	with	biological	functions	including	cell	movement,	growth,	proliferation	and	signaling.	However,	unique	to	the	IDH1R132H	+	p53R273H	is	the	association	with	cellular	assembly,	organization,	function	and	maintenance.	Indicating,	the	addition	of	the	p53R273H	mutation	may	create	a	stress	resistance,	allowing	cells	to	regain	functional	abilities.	There	are	a	number	of	genes	being	up	and	downregulated	similarly	between	the	two	mutant	cell	lines,	but	each	line	contains	a	few	unique	regulations.	In	the	IDH1R132H	cells,	CECR2	and	IFITM10	are	being	upregulated,	while	SLC38A5,	CPXM1,	and	PLPP2	are	being	downregulated.	Conversely,	RSAD2	and	MMP3	are	upregulated	in	IDH1R132H	+	p53R273H,	whereas	CD248,	IQCA1,	and	CLDN10	are	being	downregulated.	Each	gene	is	unique	in	function,	but	perhaps	the	most	interesting	is	the	upregulation	of	MMP3	in	the	
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IDH1R132H	+	p53R273H	cell	line.	MMP3	(Matrix	Metallopeptidase	3)	is	a	key	enzyme	required	for	extracellular	matrix	breakdown,	and	heavily	involved	in	cellular	development,	tissue	remodeling	and	metastasis,	with	direct	association	to	glioma	progression.	Further,	CLDN10	(Claudin	10)	is	an	enzyme	heavily	involved	in	maintaining	cell	polarity.	CLDN10	is	downregulated	in	the	IDH1R132H	+	p53R273H	cells,	supporting	the	claim	that	these	cells	are	losing	polarity	as	they	transition	to	an	invasive	phenotype.	The	platform	for	repeating	this	series	is	set	for	future	studies,	where	the	cell	lines	will	be	replicated	and	sequenced	for	a	full	analysis	of	RNA	transcriptome	and	DNA	methylome	sequencing.	Importantly,	the	drastic	phenotypic	differences	in	3D	culturing,	as	well	as	clustering	from	next-generation	sequencing	data	are	strong	indications	that	these	mutations	are	causing	the	predicted	genetic	and	molecular	changes.		
Targeting	the	YAP-TEAD	Interaction	for	Drug	Development	There	is	an	unmet	need	to	find	new	drugs	in	cancer	development	that	target	selectively	in	signaling	pathways	for	cancer	cell	growth,	while	having	minimal	effects	on	normal	tissues.	The	Hippo	pathway	has	been	continuously	demonstrated	as	an	important	pathway	for	growth	control	and	tissue	regeneration	in	organisms	ranging	from	Drosophila	to	humans	and	may	be	the	key	to	finding	pathways	that	can	be	manipulated	for	successful	molecular	development	(Zhou	et	al.).		It	has	been	shown	that	the	loss	of	TEAD	has	little	consequence	on	normal	liver	growth	while	suppressing	tumorigensis	driven	by	YAP	overexpression	(Zhou	et	al.).	Targeting	the	YAP	binding	surface	on	TEAD,	by	both	designing	a	peptide	
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molecule	that	mimics	the	region	of	YAP	bound	to	TEAD	in	the	structure	and/or	a	small	molecule	that	selectively	blocks	any	of	the	three	important	binding	regions	between	YAP	and	TEAD,	might	be	an	effective	strategy	to	abolish	the	YAP-TEAD	interaction	and	may	have	anticancer	potential	(Chen,	Loh	and	Song).	So	far,	multiple	compounds	have	been	created	for	use	in	YAP-TEAD	screenings.	Collectively,	derivatives	of	TEAD1,	TEAD2,	and	TEAD4	are	either	complete	or	in	the	process	of	being	constructed	for	these	screens.	Future	results	from	these	compounds	will	likely	lead	to	inhibitory	compounds	that	are	specific	to	the	YAP-TEAD	interaction.	By	having	the	ability	to	inhibit	the	YAP-TEAD	interaction,	YAP	dependent	transcription	can	be	controlled,	potentially	halting	tumor	progression.		
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	Figure	17.	Conceptual	Model	of	Secondary	Glioblastoma	Initiation	and	
Progression.	Progenitor	astrocytes	normally	differentiate	unless	they	experience	mutations	that	drive	them	to	become	tumorigenic.	Normal,	healthy	astrocytes	will	lose	AL1	levels	as	they	undergo	differentiation	in	order	to	become	an	adult	astrocyte.	However,	if	the	IDH1R132H	mutation	is	acquired,	that	differentiation	pathway	is	blocked,	and	the	metabolically	stressed	astrocytes	retain	high	AL1	levels.	Data	from	the	TCGA	indicates	that	as	these	cells	become	more	malignant,	they	concomitantly	lose	AmotL1	expression.			 	
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